Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 4

1.

Multiple myeloma

Multiple myeloma is a neoplastic plasma cell disorder characterized by clonal proliferation of malignant plasma cells in the bone marrow microenvironment, monoclonal protein in the blood or urine, and associated organ dysfunction (Palumbo and Anderson, 2011). [from OMIM]

MedGen UID:
10122
Concept ID:
C0026764
Neoplastic Process
2.

Multiple myeloma

A malignant plasma cell tumor growing within soft tissue or within the skeleton. [from HPO]

MedGen UID:
505979
Concept ID:
CN005898
Finding
3.

Inhibition

MedGen UID:
5809
Concept ID:
C0021469
Molecular Function
4.

selumetinib

An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers. [from NCI]

MedGen UID:
453372
Concept ID:
C2980074
Pharmacologic Substance

Display Settings:

Format

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...